Overview

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmacyclics LLC.
Treatments:
Docetaxel
Motexafin gadolinium